Clinical Trial Update: Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ASP3082 in patients with metastatic or locally advanced non-small cell lung cancer and pancreatic ductal adenocarcinoma, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• ASP3082

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING